Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Grace P. Chai
Observed name:
Grace Chai
Institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research
Observed institutions:
United States Food and Drug Administration,
Center for Drug Evaluation and Research,
United States Public Health Service
ORCID:
0000-0001-7893-723X
Observed ORCID:
0000-0001-7893-723X
OpenAlex ID:
A5000198423
Trends of Outpatient Prescription Drug Utilization in US Children, 2002–2010
2012
·
Grace Chai
, Laura Governale
, et al.
·
PEDIATRICS
·
424
Impact of Pediatric Exclusivity on Drug Labeling and Demonstrations of Efficacy
2014
·
Gerold T. Wharton
, M. Dianne Murphy
, et al.
·
PEDIATRICS
·
106
Trends in Incident Prescriptions for Behavioral Health Medications in the US, 2018-2022
2024
·
Grace Chai
, Jing Xu
, et al.
·
JAMA Psychiatry
·
65
Repeated or Continuous Medically Supervised Ketamine Administration Associated with Hepatobiliary Adverse Events: A Retrospective Case Series
2021
·
Samantha Cotter
, Jennie Wong
, et al.
·
Drug Safety
·
31
PDF
Trends and economic drivers for United States naloxone pricing, January 2006 to February 2017
2018
·
Matthew Rosenberg
, Grace Chai
, et al.
·
Addictive Behaviors
·
20
New Opioid Analgesic Approvals and Outpatient Utilization of Opioid Analgesics in the United States, 1997 through 2015
2018
·
Grace Chai
, Jing Xu
, et al.
·
Anesthesiology
·
16
Patterns of opioid analgesic use in the U.S., 2009 to 2018
2020
·
Corinne Woods
, Grace Chai
, et al.
·
Pain
·
11
Food and Drug Administration Beyond the 2001 Government Accountability Office Report: Promoting Drug Safety for Women
2021
·
Marjorie R. Jenkins
, Monica A. Munoz
, et al.
·
Journal of Women s Health
·
10
The impact of hydrocodone rescheduling on utilization, abuse, misuse, and overdose deaths
2023
·
Sara Karami
, Adebola Ajao
, et al.
·
Pharmacoepidemiology and Drug Safety
·
7
PDF
Phosphodiesterase type 5 inhibitor use among pregnant and reproductive‐age women in the United States
2020
·
Wei Liu
, Talia J. Menzin
, et al.
·
Pharmacoepidemiology and Drug Safety
·
7
Variations in US county‐level trends in buprenorphine use, 2018–2022
2025
·
Taylor W. Lefler
, Grace Chai
, et al.
·
Addiction
·
2
Use of Proprietary Names by Prescribers for Discontinued Brand Drug Products With Existing Generic Equivalents
2012
·
Chi-Ming Tu
, Kellie Taylor
, et al.
·
Drug Information Journal
·
2
Adverse Reactions Identified after Approval of Novel Medicines: Analysis of 339 New Molecular Entities and Therapeutic Biologics
2026
·
Ellen Pinnow
, Brendan Day
, et al.
·
Clinical Pharmacology & Therapeutics
·
1
Abstract 11942: Myopathy and Rhabdomyolysis With Concomitant Use of Ticagrelor and High-intensity Statins in the Elderly
2019
·
Mohamed Mohamoud
, Daniel Woronow
, et al.
·
Circulation
Use of Proprietary Names by Prescribers for Generic Products
2017
·
Vicky Borders-Hemphill
, Irene Z. Chan
, et al.
·
Therapeutic Innovation & Regulatory Science
Response to Consumer Healthcare Products Association letter to “Trend in rates of acetaminophen‐related adverse events in the United States”
2017
·
Tracy Pham
, Jacqueline M. Major
, et al.
·
Pharmacoepidemiology and Drug Safety
Show more works
View as search
Works count:
16
Citation count:
702
H-index:
8
I10-index:
8
Year
Topic
Type